BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target
BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.
Stocks · News reference
Innate Pharma Announces Updated Timing for PACIFIC-9 Phase 3 Trial Data Readout
Innate Pharma reported that AstraZeneca has adjusted the expected timeline for the high-level data readout of the Phase 3 PACIFIC-9 clinical trial to the first half of 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Innate Pharma H1 2026 Earnings Call Transcript
Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10